First Time Loading...

Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.155 AUD 6.45% Market Closed
Updated: May 7, 2024

Mesoblast Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mesoblast Ltd
Revenue Peer Comparison

Comparables:
IMM
CSL
CUV
TLX
PYC

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Mesoblast Ltd
ASX:MSB
Revenue
$7.5m
CAGR 3-Years
-23%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Revenue
AU$256.6k
CAGR 3-Years
-61%
CAGR 5-Years
-45%
CAGR 10-Years
-24%
CSL Ltd
ASX:CSL
Revenue
$14.2B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
10%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Revenue
AU$87.3m
CAGR 3-Years
31%
CAGR 5-Years
25%
CAGR 10-Years
42%
Telix Pharmaceuticals Ltd
ASX:TLX
Revenue
AU$502.5m
CAGR 3-Years
359%
CAGR 5-Years
381%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Revenue
AU$21.5m
CAGR 3-Years
99%
CAGR 5-Years
377%
CAGR 10-Years
32%

See Also

What is Mesoblast Ltd's Revenue?
Revenue
7.5m USD

Based on the financial report for Dec 31, 2023, Mesoblast Ltd's Revenue amounts to 7.5m USD.

What is Mesoblast Ltd's Revenue growth rate?
Revenue CAGR 5Y
-14%

Over the last year, the Revenue growth was -19%. The average annual Revenue growth rates for Mesoblast Ltd have been -23% over the past three years , -14% over the past five years .